BLATT LAWRENCE 4

Accession 0001567619-20-018001

CIK 0001799448other

View on SEC.gov Company Profile

Filed

Oct 19, 8:00 PM ET

Accepted

Oct 20, 4:55 PM ET

Size

42.3 KB

Accession

0001567619-20-018001

Insider Transaction Report

Form 4

Period: 2020-10-20

Aligos Therapeutics, Inc.ALGS

BLATT LAWRENCE

DirectorPresident and CEO

Transactions

Conversion
Common Stock
2020-10-20+13,671→ 13,671 total(indirect: See footnote)
Conversion
Common Stock
2020-10-20+3,394→ 17,065 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2020-10-20−41,016→ 0 total(indirect: See footnote)
→ Common Stock (41,016 underlying)
Conversion
Series B-2 Preferred Stock
2020-10-20−1,452→ 0 total(indirect: See footnote)
→ Common Stock (1,452 underlying)
Conversion
Common Stock
2020-10-20+21,695→ 113,423 total(indirect: See footnote)
Conversion
Series B-1 Preferred Stock
2020-10-20−50,712→ 0 total(indirect: See footnote)
→ Common Stock (50,712 underlying)
Conversion
Common Stock
2020-10-20+13,671→ 13,671 total(indirect: See footnote)
Conversion
Common Stock
2020-10-20+1,452→ 18,517 total(indirect: See footnote)
Conversion
Series B-1 Preferred Stock
2020-10-20−3,394→ 0 total(indirect: See footnote)
→ Common Stock (3,394 underlying)
Conversion
Series B-2 Preferred Stock
2020-10-20−1,452→ 0 total(indirect: See footnote)
→ Common Stock (1,452 underlying)
Conversion
Common Stock
2020-10-20+122,601→ 122,601 total(indirect: See footnote)
Conversion
Common Stock
2020-10-20+50,712→ 91,728 total(indirect: See footnote)
Conversion
Common Stock
2020-10-20+3,394→ 17,065 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2020-10-20−122,601→ 0 total(indirect: See footnote)
→ Common Stock (122,601 underlying)
Conversion
Series A Preferred Stock
2020-10-20−13,671→ 0 total(indirect: See footnote)
→ Common Stock (13,671 underlying)
Conversion
Common Stock
2020-10-20+41,016→ 41,016 total(indirect: See footnote)
Conversion
Common Stock
2020-10-20+1,452→ 18,517 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2020-10-20−13,671→ 0 total(indirect: See footnote)
→ Common Stock (13,671 underlying)
Conversion
Series B-2 Preferred Stock
2020-10-20−21,695→ 0 total(indirect: See footnote)
→ Common Stock (21,695 underlying)
Conversion
Series B-1 Preferred Stock
2020-10-20−3,394→ 0 total(indirect: See footnote)
→ Common Stock (3,394 underlying)

Holdings

Common Stock
1,237,298

Footnotes (5)

[F1]Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.
[F2]Lawrence M. Blatt Living Trust dated 8/27/14.
[F3]PENSCO Trust Company LLC Custodian FBO Dr. Lawrence Blatt IRA
[F4]Zachary David Blatt Irrevocable Trust dated 8/24/14.
[F5]Zoe Anne Blatt Irrevocable Trust dated 8/24/14.

Documents

1 file

4
doc1.xmlPrimary
FORM 4

Issuer

Aligos Therapeutics, Inc.

CIK 0001799448

→

Entity typeother

Related Parties

filerCIK 0001242110

Filing Metadata

Form type: 4
Filed: Oct 19, 8:00 PM ET
Accepted: Oct 20, 4:55 PM ET
Size: 42.3 KB

View on SEC.gov